Cetaphil® debuts global sensitive skin awareness initiative
The #1 doctor-recommended sensitive skincare brand in the U.S. is harnessing the expert voices of dermatologists and influencers in a digitally-driven awareness campaign with an entire month of science-backed educational content
Zug, Switzerland - April 5, 2022 – Beginning today, Cetaphil will premiere Sensitive Skin Awareness Month, a digitally-focused global awareness campaign that will arm consumers with science-backed guidance on how to identify and care for sensitive skin of all kinds. With 70% of women around the globe diagnosing themselves as having sensitive skin, the goal of Sensitive Skin Awareness Month is to provide first-hand access to experts and science-driven recommendations to help improve the overall quality of sensitive skin.
“For the past 75 years, Cetaphil has been driving innovation and research around sensitive skin to meet the tremendous need that millions of consumers have to better understand and care for their sensitive skin. Sensitive skin is often misunderstood, and it requires personalized care and products specifically designed for it. Through this month-long initiative at global scale, we aim to offer our sensitive skin community greater access and resources, ensuring they understand how to craft a skincare routine that is unique and tailored for them,”
CONSUMER GLOBAL BUSINESS UNIT HEAD
Throughout the month, teams around the world will work with board-certified dermatologists, influencers and skin specialists to share knowledge of sensitive skin and how Cetaphil’s new and improved formulas contain ingredients best suited to address the five Signs of Skin Sensitivity. With four specific weekly themes, these experts will use their social reach to guide consumers to learn more about their skin needs, about Cetaphil and how to confidently choose the personal regimen best for them.
The content schedule is as follows:
- Week 1, April 1 – 9: The five signs of skin sensitivity and how to identify them
- Week 2, April 10 – 16: The science of sensitive skincare as it relates to all skin types and tones
- Week 3, April 17 – 23: Sensitive skin moments and how to manage them
- Week 4, April 24 – 30: Sensitive skin regimens and the importance of building a personalized routine
To continue their sensitive skin educational journey, consumers can access additional resources and information at their local brand site, such as www.cetaphil.co.uk. Here visitors can take the Skincare Finder Quiz to better understand what products are right for their specific needs as well as find further educational content and advice. Several local social media activations will run throughout the month with the hashtag #SensitiveSkinMonth.
Seventy-five years ago a leading pharmacist created the first Cetaphil product – a gentle yet powerful formula that cleaned without stripping and moisturized without clogging. Today, Cetaphil is the #1 doctor-recommended facial skincare brand and is recognized around the world. With the help of leading global skincare experts, Galderma continues to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain the skin’s health every day. For more information, visit www.cetaphil.com.
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com
Rachel Mooney, Head of Franchise Communications, Galderma: email@example.com
1Farage, Miranda A. “The Prevalence of Sensitive Skin.” US National Library of Medicine National Institutes of Health, www.ncbi.nlm.nih.gov/pmc/articles/PMC6533878/.